Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Common Stock | Options Exercise | $464K | +20.3K | +83.54% | $22.89 | 44.5K | Feb 25, 2023 | Direct | F1 |
transaction | PFE | Common Stock | Tax liability | -$240K | -5.75K | -12.9% | $41.75 | 38.8K | Feb 25, 2023 | Direct | F2, F3 |
transaction | PFE | Common Stock | Tax liability | -$392K | -9.02K | -23.24% | $43.44 | 29.8K | Feb 25, 2023 | Direct | F4, F5 |
holding | PFE | Common Stock | 28.9K | Feb 25, 2023 | By Rule 16b-3 Plan | ||||||
holding | PFE | Common Stock | 8.53K | Feb 25, 2023 | By Spouse | F6 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -20.3K | -100% | $0.00* | 0 | Feb 25, 2023 | Common Stock | 20.3K | $22.89 | Direct |
Id | Content |
---|---|
F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
F3 | Price is the closing price of Pfizer common stock on February 24, 2023. |
F4 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
F5 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
F6 | The reporting person disclaims beneficial ownership of the shares held by spouse. |